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PIH2
ADDRESSING CHILDHOOD OBESITY IN MEXICO: SAVINGS ON HEALTH CARE
EXPENDITURES FROM REGULATING FOOD AND BEVERAGE SALES IN BASIC
EDUCATION SCHOOLS
Guajardo-Barron VJ1, Gutierrez-Delgado MC1, Rivera-Peña G2
1Mexican Ministry of Health, México, D.F., México, 2Economic Analysis Unit, México, D.F., México
OBJECTIVES: Estimate potential direct savings for the Mexican Healthcare System
generated by the operation of the Technical Guidelines for distribution of food and
beverages in establishments of basic education targeting population of 6 to 14
years of age. METHODS: The authors use the micro-simulation model Chronic
Disease Prevention (CDP) developed by the OECD-WHO for projecting health gains
and costs of treatment in a period of 100 years. The model was adjusted to accom-
modate the range of ages stated in the Guidelines and uses information of inci-
dence, prevalence, mortality, population at risk, annual unit costs and relative risk
of selected chronic diseases (diabetes mellitus type 2, hypertension, cardio- and
cerebro-vascular, hypercholesterolemia) attributable to obesity as well as the treat-
ment of obesity as disease itself for the Mexican context. Sensitivity analyses were
developed for most variables used in the model. RESULTS: Under the base case
scenario present value of potential savings in total spending on medical care asso-
ciated with the implementation of the Guidelines amount to USD$1,052.2 million in
2008. Most savings are derived from averted cases of hypertension (32.7%), obesity-
overweight (28.6%) and diabetes mellitus type II (17.8%). Results are robust to
changes in all parameters analyzed. Amounts obtained are an underestimation of
potential savings as neither expensive complications as renal failure nor other
chronic diseases attributable to obesity as arthritis, colorectal or breast cancer were
included. CONCLUSIONS: The Guidelines, developed by both Ministry of Public
Education and Ministry of Health, represent a good example of cooperation among
different sectors to solve a complex public health problem. Results shows the impor-
tance of implementing preventive interventions aimed at reducing the prevalence of
chronic diseases related to poor eating habits, inadequate physical activity and obesity
in Mexico. The implementation of the Guidelines involves significant direct savings
that can be assigned to other health needs of the Mexican population.
PIH3
RESOURCE USE AND ASSOCIATED COSTS FOR THE TREATMENT OF HEAVY
MENSTRUAL BLEEDING WITH LEVONORGESTREL RELEASING INTRAUTERINE
SYSTEM (LNG-IUS) VERSUS HYSTERECTOMY: THE BRAZILIAN PUBLIC
HEALTHCARE SYSTEM (SUS) PERSPECTIVE
Bahamondes L1, Bahamondes V1, Schiola A2, Silva AP3, Santoni NB3, Moura M4, Salem J4,
Clarck L4, Teich V4
1University of Campinas, Campinas, SP, Brazil, 2Bayer de México, S.A. de C.V., México, D.F,
México, 3Bayer Brazil, São Paulo, SP, Brazil, 4MedInsight Evidências, São Paulo, SP, Brazil
OBJECTIVES: To describe the resource utilization and the costs related to heavy
menstrual bleeding (HMB) control with either an LNG-IUS or hysterectomy in the
Brazilian Public Health System (SUS) on patients treated at the Department of
Obstetrics and Gynecology, School of Medical Sciences, University of Campinas,
Brazil. METHODS: We performed an observational retrospective descriptive study
with costs evaluation and budgetary impact calculation from data extracted from
medical files of patients diagnosed with HMB treated either with the LNG-IUS or
hysterectomy. The measured outcomes were HMB control, LNG-IUS induced com-
plications (expulsion, uterine perforation, pelvic inflammatory disease), LNG-IUS
continuation rate and hospital costs after one year, as well as, the budgetary im-
pact of the use of LNG-IUS in the treatment of HMB vs. hysterectomy. RESULTS:
Two hundred sixty-seven medical files were initially retrieved for analysis. A total
of 246 patients were included in this study, 122 received the LNG-IUS and 124 were
treated with hysterectomy. The mean age was 39.7 years in the LNG-IUS group and
47.9 in the surgery group. Mean duration of HMB in the hysterectomy group was 3.2
years, twice that of the LNG-IUS group (1.5 years) (p0.01). Of the patients treated
with LNG-IUS, 88.7% maintained the device for over one year and 83.1% had suc-
cess in bleeding control with this method. Fourteen patients had to have the LNG-
IUS removed prior to 12 months; however, only 1.6% because of failure in bleeding
control. Costs for the LNG-IUS insertion in a one-year time horizon were R$ 762.64
versus R$ 870.03 for the hysterectomy procedure. CONCLUSIONS: When applied to
the eligible population in SUS the budgetary impact of the LNG-IUS adoption was
an economy of almost R$ 3.6 million.
PIH4
ANALISIS DE COSTO-EFECTIVIDAD DEL USO DE LEVONORGESTREL-UIS FRENTE
A OTROS TRATAMIENTOS EN MENORRAGIA IDIOPATICA
Romero M1, Arango C1, Espinel F2, Karpf E1, Sanabria M1, Alvis N3
1Fundación Salutia, Bogotá, Colombia, 2Clínica de la Mujer, Bogotá, Colombia, 3Universidad de
Cartagena, Cartagena de Indias, Bolívar, Colombia
OBJECTIVOS: Establecer la Costo-efectividad de levonorgestrel-UIS (LNG-UIS) en el
tratamiento de Menorragia Idiopática comparado con otras opciones de trata-
miento (Anticonceptivo Oral Combinado, Acido Tranexámico, Acido Mefenámico y
Naproxeno). METODOLOGÍAS: Se realizo un análisis de costo-efectividad desde la
perspectiva del tercero pagador evaluando como desenlace el tiempo libre de sin-
tomatologías ganado y el número de histerectomías evitadas. Las probabilidades
de transición fueron obtenidas de estudios clínicos. Se tomaron los costos directos
de atención a precios del 2010. No se incluyó la Ablación endometrial por no ser de
uso en Colombia Se aplico un descuento del 3% anual para costos y desenlaces. Se
realizó un análisis de sensibilidad tipo Montecarlo con 2000 iteraciones y un análi-
sis univariado tipo tornado. RESULTADOS: Para una cohorte hipotética de 100
mujeres y un horizonte temporal de 5 años el costo del brazo con LNG-UIS fue de
100,993 USD frente a 116,726 USD, 127,513 USD, 103,497 y 125,330 USD (Anticoncep-
tivo Oral Combinado, Acido Tranexámico, Acido Mefenámico y Naproxeno respec-
tivamente). Con LNG-UIS se lograron 5.413 meses sin sintomatología frente a 5.110,
4.975, 5.028 y 4791 respectivamente. Con LNG-UIS se evitaron, 77 Histerectomías
frente a 58, 74,75 Y 65 respectivamente. LNG-UIS fue dominante frente a los demás
comparadores para los desenlaces analizados. El análisis de sensibilidad tipo Mon-
tecarlo mantuvo dominancia del LNG-UIS en más del 99%. CONCLUSIONES: El uso
de LNG-UIS como primera opción de tratamiento en mujeres con menorragia id-
iopática es la mejor alternativa por cuanto es menos costoso y más efectiva desde
la perspectiva del tercero pagador en Colombia.
PIH5
REPLACING MMR BY MMRV IN MEXICO: ASSESSEMENT OF COST-
EFFECTIVENESS BASED ON A DYNAMIC TRANSMISSION MODEL
Ouwens M1, Macias M2, Mascareñas De Los Santos AH3, Gomez JA4, Sauboin C5,
Carreño Manjarrez R6
1Mapi Values Netherlands, Houten, The Netherlands, 2Instituto Nacional de Pediatría, Pediatric
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5GlaxoSmithKline Biologicals, Wavre, Belgium, 6GlaxoSmithKline, México, D.F. , México
OBJECTIVES: To predict the cost-effectiveness of vaccination with measles,
mumps, rubella, and varicella (MMRV) vs MMR in Mexico. METHODS: A dynamic
mathematical model was used to reproduce the age-related incidence of varicella
and zoster. The impact of introducing varicella vaccination was predicted at pop-
ulation-level including costs and quality of life. Empirical age-specific contact rates
between individuals were used. Vaccine efficacy against varicella was assumed to
be 95% after two doses (1y and 6y). We assessed the impact of vaccination in a
base-case (coverage dose1: 90%; dose2: 80%) and in an optimal scenario (higher
coverage dose1:95%; dose2:90% and catch-up programme); and the cost-effective-
ness of replacing MMR with MMRV using 5% discount rates for benefits and costs.
RESULTS: In the long-term, MMRV vaccination is predicted to result in a 90%
decrease in varicella incidence (with short-term epidemics due to rebound effect)
and a90% decrease in zoster cases (with a temporary increase due to the assump-
tion on exogenous boosting). At 1, 5, 30, and 80 years, MMRV versus MMR is pre-
dicted to result in: - more QALYs saved (31, 209, 925, and 1306); - more complica-
tions avoided (2, 6, 132, 1864); and - less deaths (0.15, 1.09, 8.39, 28.95). Despite
increased vaccine costs vs MMR, MMRV was cost saving at all time points in terms
of GP/outpatient, hospital, indirect, and total ($7.9, $56.5, $226.9, and $331.2 million,
respectively) costs. Cost-effectiveness planes for direct and total costs indicate that
MMRV would provide more QALYs than MMR, and is cost saving. These results are
for the base-case scenario. For optimal scenario, results were similar or even better.
CONCLUSIONS: MMRV vaccination should result in significant reduction in vari-
cella and zoster cases in the long-term. We predict the replacement of MMR by
MMRV to be dominant under both scenarios.
Infection – Clinical Outcomes Studies
PIN1
THE EPIDEMIOLOGIC BURDEN OF HEPATITIS C VIRUS INFECTION IN LATIN
AMERICA
Szabo SM1, Donato BM2, Yuan Y3, Bibby M1, Jimenez-Mendez R4, Levy AR1
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb, Wallingford, CT, USA,
3Bristol-Myers Squibb, Plainsboro, NJ, USA, 4University of British Columbia, Vancouver, BC,
Canada
OBJECTIVES: Chronic infection with hepatitis C virus (HCV) is a major and growing
public health concern in many, if not all, Latin American countries. With more
efficacious therapies becoming available, decision-makers require accurate esti-
mates of disease prevalence to assess the cost-benefit ratio of new treatments for
HCV infection. These estimates are challenging to derive because HCV infection
often remains asymptomatic – and therefore undetected – until the liver has been
seriously damaged. The objective of the study was to synthesize estimates of the
epidemiologic burden of HCV from Latin America. METHODS: A systematic review
was conducted in Medline and EMBASE by two reviewers to identify population-
based estimates of HCV prevalence from Argentina, Brazil, Colombia, Mexico, Peru,
and Venezuela since 2000. Studies were only included if they were considered
methodologically adequate, and randomly sampled representative members of the
general population. Counts and rates of positive HCV tests from national blood
bank networks were also synthesized. RESULTS: Only one methodologically ade-
quate Latin American population-based survey, from Mexico, was identified; the
estimated HCV prevalence was 1.4% (1.1%-1.6%). Estimates of HCV prevalence
among blood donors were: 0.66% (Argentina, 2008), 0.53% (Brazil, 2007), 0.57% (Co-
lombia, 2006), 0.66% (Mexico, 2007), 0.81% (Peru, 2007), and 0.37% (Venezuela, 2005).
CONCLUSIONS: Based on the review, Mexico is the only Latin American country
with robust estimates of HCV prevalence; the potential societal burden is enor-
mous as about 1.5% of the population is infected. Rates from blood donors under-
estimate true HCV prevalence; and the differences between population-based and
blood donor estimates for Mexico help frame the extent of that underestimate.
These population-based prevalence estimates, and the prevalence estimates from
blood donors, may be useful for inclusion in disease models. Discrepancies be-
tween estimates from the different sources underscore the need for methodolog-
ically-rigorous epidemiologic studies to maximally inform decision-makers in
Latin America.
Infection – Cost Studies
PIN2
FACING CRITICAL HEALTH EVENTS: ECONOMIC IMPACT OF AH1N1 FLU
EPIDEMIC IN THE MEXICAN HEALTH SECTOR, 2009-2010
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Gutierrez-Delgado C, Gómez-Fraga S
Mexican Ministry of Health, México, D.F., México
OBJECTIVES: Analyze the economic impact of the A-H1N1 flu epidemic for the
health sector in Mexico in the 2009-2010 period, that resulted in the first pandemic
of the XXI century, in order to plan the resources provision and review policies
aimed to deal with similar future events. METHODS: The exercise had several
stages. First, a collect of the expenditures incurred by the health sector at federal
level between April 2009 and August 2010 was made. Second, the collected infor-
mation was classified into two areas of analysis: a) health care expenditures, and b)
additional costs from purchasing and application of vaccines, medical equipment,
drugs and health products, federal support to states, and national media cam-
paigns. Third, health care expenditure and expenditure by area of analysis was
estimated by aggregating all costs. RESULTS: Total federal expenditure related to
addressing the epidemic in the health sector was estimated in USD$ 733.3 million,
32% linked to health care and 93.7% exercised in 2009, corresponding to 11.2% of the
total health expenditure budget for this year. This expenditure involved medical
attention of 368 thousands patients, purchasing and application of 6.8 million of
anti-flu seasonal vaccines and 30 million of anti-AH1N1flu vaccines. For health
care, a total expenditure of USD$ 216.7 million was estimated, 80% exercised in
2009, that involves medical attention of 330 thousand patients. A total expenditure
of USD$ 516.3 million was estimated for additional costs, more than 99% exercised
in 2009. The main component of this area was the purchase and application of
A-H1N1 flu vaccine (USD$ 228.8 million). CONCLUSIONS: The exercise allows
knowing the mayor spending areas and generates evidence to strengthen the fi-
nancial and operational planning processes to face similar health events, such as
the need to anticipate resources and contingency funds in addition to administra-
tive and operational processes.
PIN3
PURSUING FINANCIAL SUSTAINABILITY TO FULFILL THE MILLENIUM
DEVELOPMENT GOAL SIX IN A FRAGMENTED SYSTEM. THE EXPERIENCE OF
THE UNIVERSAL ACCESS TO ANTIRETROVIRAL DRUGS IN MÉXICO 2007-2009
Rivera-Peña G, Rios-Arenas D, Gutierrez-Delgado C
Economic Analysis Unit, México, D.F., México
OBJECTIVES: To calculate the average annual cost per ART in IMSS, ISSSTE and
MoH. To analyze the financial requirements for the provision of ART through the
Universal Access Program to Antiretroviral Drugs (PAUMA) lead for the MoH and its
implications for drug procurement policies at national level in the short and me-
dium terms.METHODS:We obtained data about patients under ART in 2007 for the
three main institutions mentioned and in 2009 only for MoH. Information was
analyzed to identify ART prescriptions according to official recommendations. Av-
erage annual cost of ART per patient and institution was estimated for 2007 and
2009. Projections of the financial requirements to ensure the provision of ART
through the PAUMA for the period 2010-2017 were estimated. Analysis was devel-
oped in STATA 9.2. RESULTS: In 2007 average annual cost of ART for the three main
institutions was MXP$64,800; per institution were as follow: ISSSTE MXP$74,300;
IMSS MXP$67,600 and MoH MXP$61,600. Information for the MoH indicates that
average annual cost of ART decreased between 2007 and 2009 by around 10.2% (in
2009 was MXP$55,300). First 20 ART options are prescribed to 80% of the patients
and represent around 73% of the total costs in 2009. Projections for PAUMA in the
period 2010-2017 indicate that on average annually 7,000 new patients require ART
and 5,000 deaths will occurred. Assuming new cases, deaths and prices of antiret-
roviral drugs remain constant the average annual increase in financial require-
ments for PAUMA to ensure ART in the period studied will be 5.6%. CONCLUSIONS:
Results generate evidence to strengthen the decision making, monitoring, contain-
ment costs, and purchase of antiretroviral drugs processes. It also provides infor-
mation to allow policy makers optimize the use of limited public resources to
support the demand for ART through the financial armor that contributes to main-
tain universal coverage, allowing the fulfillment of Goal 6 of the Millennium Devel-
opment Goals.
PIN4
ECONOMIC IMPACT OF COMMUNITY ACQUIRED PNEUMONIA
HOSPITALIZATIONS IN ADULTS IN SIX COUNTRIES IN LATIN AMERICA
Rosado-Buzzo A1, Garcia-Mollinedo L1, Camacho-Cordero L1, Roberts CS2,
Mould-Quevedo JF2, Trejo-Martinez A1, Luna-Casas G1
1Links & Links S.A, de C.V., México, D.F., México, 2Pfizer, Inc., New York, NY, USA
OBJECTIVES:To estimate the economic impact of community acquired pneumonia
(CAP) in adults over 50 years of age in Argentina, Brazil, Chile, Colombia, Mexico,
and Venezuela.METHODS: Local data sources were used to estimate the number of
cases of hospitalized pneumonia cases from ICD-9 codes in the year 2009 in adults
50 years of age. CAP episodes were estimated from pneumonia proportionally by
age based on prior publications that compared ICD-9 coded hospitalizations to
confirmed CAP by chart review. Resource use was estimated from treatment guide-
lines and expert opinion and multiplied by local unit costs to derive total costs.
Indirect costs to patients and caregivers were estimated by average wages times
participation rate by age. Mortality cost was estimated by discounted life expec-
tancy times wage rates and participation rates by age group. Costs were converted
to USD by exchange rates to facilitate comparison. RESULTS: The average cost of
CAP hospitalizations in adults was (USD): Argentina$32,241; Brazil$29,457;
Chile$26,936; Colombia$23,656; Mexico$21,018; Venezuela$22,536. In adults
65 years old, indirect costs comprised 1.5% of cost associated with hospitaliza-
tions (range: 0.2% - 2.5%) and mortality costs comprised 16% (range: 3% - 24%). In
adults 65 direct costs were over 95% of episode costs. The total cost of CAP hos-
pitalizations in adults was (USD$Mil): Argentina$697; Brazil$3,624; Chile$445;
Colombia$347; Mexico$941; Venezuela$387. As a proportion of the total pop-
ulation, CAP hospitalizations cost approximately $74 per person 50 years old per
year (range $42-$108) and $148 per person over 65 per year (range $95-$235).
CONCLUSIONS: CAP hospitalizations represent a significant economic burden in
adults across Latin America countries. Nearly one quarter of the cost burden
among adults65 includes indirect costs, while the economic burden among older
patients is driven by direct costs and high incidence.
PIN6
EVALUACION COSTO-EFECTIVIDAD DEL USO DE LINEZOLID EN EL
TRATAMIENTO DE NEUMONIAS NOSOCOMIALES EN MÉXICO
Vargas-Valencia JJ1, Sotelo-Guzmán M1, Díaz-Ponce H2, Galindo-Suárez RM2,
Muciño-Ortega E2, Mould-Quevedo JF3
1Econopharma Consulting S.A. de C.V., México, D.F., México, 2Pfizer S.A. de C.V., México, D.F.,
México, 3Pfizer, Inc., New York, NY, USA
OBJECTIVOS: La neumonía nosocomial (NN) es la segunda causa más frecuente de
infección intrahospitalaria, la infección más frecuentemente adquirida en la uni-
dad de cuidados intensivos (UCI) y la primera causa de mortalidad por infecciones
intrahospitalarias. El objetivo de esta investigación fue estimar el costo-efectividad
del uso de linezolid en el tratamiento de la NN en comparación con el uso de
vancomicina y teicoplanina, desde la perspectiva del Instituto Mexicano del Seguro
Social (IMSS). METODOLOGÍAS: Se construyó un árbol de decisiones que compara
el uso de linezolid inyectable, seguido por linezolid oral (600mg dos veces/día),
vancomicina inyectable (1000mg dos veces/día) y teicoplanina inyectable (400mg
dos veces el primer día, días subsecuentes: 400mg) en el tratamiento de NN (hori-
zonte temporal: 38 días). Se evalúan la tasa de éxito microbiológico, los días de
estancia hospitalaria (en piso y UCI) y los costos médicos directos. Se realizó una
revisión de literatura para extraer la tasa de respuesta. La relación de insumos
(laboratorios, consultas y medicamentos) y procedimientos, así como el manejo
hospitalario se extrajó de la literatura y se complementó con opinión de expertos.
Los costos corresponden al IMSS para el año 2010. Se realizó análisis de sensibilidad
probabilístico. RESULTADOS: La tasa de éxito microbiológico del tratamiento con
linezolid fue de 64%, 59.5% con vancomicina (p0.336) y 44.1% con teicoplanina
(p0.001). Esto se refleja en una menor estancia en UCI, con 17.4 días para linezolid,
21.26 días con vancomicina y 21.82 días para teicoplanina. El costo total de trata-
miento con linezolid fue $777,873.14, siendo menor respecto del de vancomicina
($865,186.96) y teicoplanina ($931,983.09). Las curvas de aceptabilidad muestran
que linezolid es costo ahorrador con respecto a vancomicina o teicoplanina.
CONCLUSIONES: En el tratamiento de las NN en el contexto del IMSS, linezolid
presenta dominacia débil sobre vancomicina y dominancia absoluta sobre teico-
planina.
PIN7
COST-EFFECTIVENESS ANALYSIS OF ANTI-PNEUMOCOCCAL VACCINES VERSUS
NO VACCINATION IN EL SALVADOR
Dueñas MDL1, Lutz M2, Morales G2, Strutton DR3, Roberts C4, Cuesta G2, Farkouh RA3
1Hospital Centro Pediátrico, San Salvador, El Salvador, 2Pfizer S.A., La Aurora, Heredia, Costa
Rica, 3Pfizer, Inc., Collegeville, PA, USA, 4Pfizer, Inc., New York, NY, USA
OBJECTIVES: In 2009, it was estimated that there were 12.000 to 28.000 deaths in
Latin America related to Streptococcus pneumonia infections in pediatric popula-
tion under 5 years old. Currently, in El Salvador, Prevenar 7 (PCV-7) is the anti-
pneumococcal vaccine used. The aim of this study was to estimate the cost-effec-
tiveness and cost-utility of immunization strategies based on pneumococcal
conjugated vaccines (PCVs) in El Salvador, from an institutional perspective.
METHODS:A decision tree model was used to asses economic and health impact of
PCVs in children under 2 years old. The alternatives compared were: no vaccination
(comparator), PCV-7, PCV-10 and PCV-13. The effectiveness measures were: child
illness avoided, life years gained (LYs) and quality-adjusted life years (QALYs)
gained. Effectiveness and utilities were obtained from literature. Local costs (ex-
pressed in 2009 $US) and epidemiology (data from 2009) were obtained from El
Salvador=s Ministry of Health database. The model included vaccine dosage sched-
ules approved in WHO prequalification and/or El Salvador MoH calendar at the
time of data collection (dec-2010). Univariate sensitivity analysis was performed.
The time horizon was one year and the discount rate was 3%. RESULTS: Results
show that immunization is cost-saving against no-vaccination. PCV-13 gained the
highest number of QALYs (898) against PCV-10 (637) and PCV-7 (460). PCV-13 pre-
vented 359 illnesses and gained 998 LYs. PCV-10 and PCV-7 prevented 257 and 228
illnesses and gained 707 and 511 LY=s, respectively. These results were robust to
variations in herd immunity and impact adjustments of PCV10 immunogenicity.
CONCLUSIONS: In El Salvador, immunization strategies based on 7, 10 and 13-
valent PCV=s would be cost-saving interventions. Health outcomes and savings of
PCV-13 are greater than those estimated for 7 and 10-valent PCV=s.
PIN8
EVALUACION ECONOMICA DE LA EXTENSION DE PROFILAXIS CONTRA CMV DE
100 A 200 DIAS EN RECEPTORES DE TRASPLANTE RENAL CON ALTO RIESGO
(D / R)
Morales Buenrostro LE
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubiran, México, DF, México
OBJECTIVOS: Traducir los beneficios clínicos de extender el período de profilaxis
con Valganciclovir de 100 a 200 días en un análisis de costo-efectividad de largo
plazo en la etapa postrasplante en pacientes con alto riesgo de enfermedad por
Citomegalovirus (CMV) (D / R). METODOLOGÍAS: Se utilizó un Modelo Markov
para simular los costos de los diferentes estadios de la enfermedad. Los horizontes
temporales evaluados son: menor a un año, un año, cinco años y diez años. La
población modelada son pacientes receptores de trasplante renal (RTR) con alto
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